Reads DNA and RNA in real time by threading single molecules through tiny protein pores and measuring the electrical signal.
At a glance
- Depends onMidstream position: 3 outgoing, 3 incoming connections
- Scale
Reads DNA and RNA in real time by threading single molecules through tiny protein pores and measuring the electrical signal.
What this company is and how it runs — written from structure, not news.
Oxford Nanopore Technologies sequences DNA and RNA by threading single molecules through engineered CsgG protein nanopores — tiny biological pores embedded in a membrane inside a flow cell — and reading each base from the electrical signal it disturbs as it passes through. Because the protein pore degrades after each run, every sequencing experiment consumes a fresh flow cell that must be individually produced, quality-checked, and cold-chain shipped from Oxford Science Park, so the handheld MinION and the larger lab instruments are really delivery vehicles for a recurring biological consumable. That protein production cannot simply be sped up when demand rises — each batch requires its own quality control to confirm the pore geometry actually works — which means manufacturing capacity, not software or device supply, is what limits how fast the business can grow. The whole model rests on a licence from the University of Oxford for the CsgG pore design, and if that licence were ever lost or contested, there is no substitute protein waiting: every flow cell format would have to restart the engineering and regulatory process from scratch.
How does this company make money?
The company sells its sequencing devices — MinION, GridION, and PromethION — at low margins, essentially to get hardware into laboratories. The recurring money comes from flow cells, which customers must buy fresh for every sequencing run they perform. For larger PromethION installations, the company also earns revenue through service contracts and software licensing fees.
What makes this company hard to replace?
Laboratories that have built their workflows around receiving a continuous stream of sequencing data in real time cannot easily move to competing platforms that require hours of upfront library preparation and return results in batches rather than as the molecule is read. Switching also means reconfiguring any laboratory information management system that has been set up to receive data from a MinION. For teams doing outbreak surveillance in the field, no desktop sequencer can replace the MinION's pocket-sized portability, so their deployment protocols have no direct alternative.
What limits this company?
The CsgG protein pores that make sequencing work must be grown in biological expression systems, and each batch has to be individually checked to confirm the pores are the right shape and produce the right electrical signal before they can be built into a flow cell. That biological production process cannot simply be sped up. It, not the hardware manufacturing or the software, is the ceiling on how many flow cells can be made and shipped at any given time.
What does this company depend on?
The company cannot operate without four things: the engineered CsgG protein nanopores licensed from the University of Oxford, specialized ASIC chips from semiconductor fabricators that detect the tiny current changes the pores produce, cold-chain logistics providers that keep flow cells at the right temperature from Oxford Science Park to the customer, and regulatory clearances for in vitro diagnostic use in each target market.
Who depends on this company?
Academic genomics laboratories rely on the company for real-time sequencing in the field and for rapid pathogen identification — without it they would have no portable option. Clinical laboratories running infectious disease surveillance would fall back on slower sequencing methods that cannot return results the same day. Agricultural genomics programs doing on-site crop and livestock genetic screening would lose the only portable DNA analysis tool suited to fieldwork.
How does this company scale?
Software updates and new sequencing devices can be rolled out across many users at relatively low extra cost. But every single sequencing run still requires a freshly made flow cell containing biological CsgG protein pores that must be individually produced and quality-checked. That protein production step does not get faster just because demand rises, so it remains the fixed constraint no matter how many devices are in the field.
What external forces can significantly affect this company?
Brexit trade rules create friction for moving biological materials between the UK manufacturing site and customers in the European Union. Chinese restrictions on genomics technology imports block or limit access to one of the world's largest sequencing markets. And when global logistics networks are disrupted — as they were during recent global crises — temperature-sensitive flow cells can degrade in transit before they ever reach a lab.
Where is this company structurally vulnerable?
If the University of Oxford licence covering the CsgG pore design were revoked, expired, or successfully challenged in court, the company would have no approved pore to put in its flow cells. Every product format would need to be re-engineered and re-approved from the beginning, and both the single-use consumable model and the real-time sequencing capability would collapse at the same time, because both depend entirely on that one licensed pore design.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
CompanyGraph